MAPT and Alzheimer disease: The recent development of 18F-fluorinated radioligands for positron-emission-tomography (PET) studies of tau aggregates intensely accelerated research in the field of tau imaging in AD and non-AD tauopathies (Villemagne and Okamura, 2016).